甘李药业：公司一直高度重视股东回报，积极响应监管部门号召

Core Viewpoint - Ganne Li Pharmaceutical (603087) emphasizes its commitment to shareholder returns and compliance with regulatory guidelines, planning to distribute approximately 900 million yuan in cash dividends for the year 2024 [1] Group 1: Shareholder Returns - The company has stated that it places high importance on shareholder returns and actively responds to regulatory calls [1] - For the year 2024, the total cash dividend is expected to be around 900 million yuan [1] - Future profit distribution will strictly adhere to the company's articles of association and the profit distribution policy approved by the shareholders' meeting [1] Group 2: Profit Distribution Policy - The profit distribution will consider factors such as the company's profitability, cash flow status, future investment plans, and industry development trends [1] - The company aims to provide stable and reasonable returns to shareholders while ensuring long-term sustainable development [1]